Hyderabad: Biophore India Pharmaceuticals on Monday announced that it has receiv .. nnRead more at: nhttps://health.economictimes.indiatimes.com/news/pharma/drug-approvals-launches/biophore-its-subsidiary-zenara-pharma-receive-first-approval-for-cannabidiol-in-india/100251790
Akums enters into a joint association with Leiutis and Biophore for introducing first-of-its-kind therapeutics
Zenara Pharma Launches Generic Of Paxlovid For COVID-19 In India
BAUDETTE, Minn.--(BUSINESS WIRE)--ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced the launch of Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg.
Hyderabad-based Biophore India Pharmaceuticals has developed and started manufacturing the key intermediates of Nirmatrelvir, one of the active ingredients of Paxlovid, the latest anti-COVID-19 therapy, approved by the US FDA through the emergency use authorisation route.
Biophore India Pharmaceuticals has received license from Medicines Patent Pool (MPP) on behalf of originator company MSD, a trade name of Merck & Co., Inc, Kenilworth, New Jersey, USA, to manufacture and market molnupiravir API and finished product in capsules form.
Natco Pharma Limited and Biophore India Pharmaceuticals have received the license from the Medicines Patent Pool (MPP), Switzerland, to manufacture and market molnupiravir, a drug that is indicated in several countries in the Covid-19 treatment protocol.
Biophore India Pharmaceuticals has announced that it has applied for DCGI emergency use approval of Aviptadil Inhalation for marketing in India to treat moderate to severe cases of COVID-19. Biophore has developed Aviptadil and is backward integrated with in-house API. The company has also informed that it will be commencing commercial production immediately after the approval is received.
Advance Market Analyticsreleased the research report ofGlobal MeglumineMarket, offers a detailed overview of the factors influencing the global business scope.Global Meglumine Market research report shows the latest market insights with upcoming trends and breakdown of the products and services.The report provides key statistics on the market status, size, share, growth factors of the Global Meglumine.This Report covers the emerging player’s data, including: competitive situation, sales, revenue and global market share of top manufacturers are Merck & Co. Inc. (United States), Tianma Microelectronics (China), Libang Healthcare Group (China), Shanghai New Hualian Pharmaceutical co.,ltd (China), Biophore India Pharmaceuticals Pvt Ltd (India), EstechPharma Co Ltd (South Korea), Sanofi S.A. (France), Schering AG (Germany), Xian Libang Pharmaceutical Co.Ltd (China) and Nippi Incorporated (Japan).
Zenara Pharma, a fully owned subsidiary of Biophore India Pharmaceuticals, has announced that it has received approval from the Drugs Controller General of India (DCGI), to manufacture and sell Favipiravir tablets as a treatment option for patients with mild to moderate symptoms of COVID-19. The tablet, which will be sold under the brand name ‘Favizen’, is being manufactured at Zenara’s US FDA approved facility in Hyderabad.